Benchmark Reiterates Buy on Emergent BioSolutions, Maintains $8 Price Target
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Robert Wasserman has reiterated a Buy rating on Emergent BioSolutions (NYSE:EBS) and maintained a price target of $8.
July 03, 2024 | 1:49 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Benchmark analyst Robert Wasserman has reiterated a Buy rating on Emergent BioSolutions (NYSE:EBS) and maintained a price target of $8.
The reiteration of a Buy rating and the maintenance of a price target by a reputable analyst can positively influence investor sentiment and potentially drive short-term price appreciation for EBS.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100